Acquired Company

Janssen completed acquisition of bermekimab from XBiotech on 12/30/2019 for US $750 million.

XBiotech Inc. is an Austin, Texas-based biopharmaceutical company at the forefront of developing True Human monoclonal antibodies aimed at treating a range of diseases. By leveraging cutting-edge technology to utilize human immune cells, XBiotech is committed to providing safer and more efficacious therapeutic options. With a strong and diverse product pipeline, the company holds a strategic position in the biotherapeutics market, focusing on enhancing patient outcomes while addressing substantial unmet medical needs across various therapeutic areas. Show more

Location: 5217 WINNEBAGO LANE, AUSTIN, TX, UNITED STATES, 78744, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, USA | Website: https://www.xbiotech.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

76.52M

52 Wk Range

$2.09 - $3.62

Previous Close

$2.51

Open

$2.53

Volume

62,535

Day Range

$2.41 - $2.66

Enterprise Value

-84.99M

Cash

147.4M

Avg Qtr Burn

-4.259M

Insider Ownership

36.61%

Institutional Own.

8.05%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Natrunix + Methotrexate (MTX) Details Rheumatoid arthritis, Autoimmune disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Hutrukin Details Brain disease, Ischemic stroke	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Natrunix w/ ON+5FU+LV Details Cancer, Pancreatic cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bermekimab Details Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.